KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Asset Writedowns and Impairment (2020 - 2024)

Vir Biotechnology recorded quarterly Asset Writedowns and Impairment of $11.0 million in Q4 2024, up 300.07% quarter-over-quarter from $2.8 million in Q4 2023, and up 300.07% year-over-year from $2.8 million in Q1 2024.

Vir Biotechnology's Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $11.0 million for Q4 2024.

  • In Q4 2024, Asset Writedowns and Impairment rose 300.07% year-over-year to $11.0 million; the TTM figure through Dec 2025 stood at $11.0 million (down 20.0% YoY), while the FY2024 annual figure was $14.6 million, up 50.65% from the prior year.
  • Asset Writedowns and Impairment came in at $11.0 million for Q4 2024 at Vir Biotechnology, up from $2.8 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $11.0 million in Q4 2024 to a low of $800000.0 in Q3 2020.
  • A 3-year average of $4.9 million and a median of $2.8 million in 2023 frame the typical range for Asset Writedowns and Impairment.
  • On a YoY basis, Asset Writedowns and Impairment climbed as much as 300.07% in 2024 and fell as far as 300.07% in 2024.
  • Vir Biotechnology's Asset Writedowns and Impairment stood at $800000.0 in 2020, then surged by 244.88% to $2.8 million in 2023, then soared by 300.07% to $11.0 million in 2024.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $11.0 million, $2.8 million, and $800000.0 for Q4 2024, Q4 2023, and Q3 2020 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Vir Biotechnology 1.33 Bn 1.33 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 11.04 Mn
Dec 31, 2024 11.04 Mn
Dec 31, 2023 2.76 Mn
Dec 31, 2023 2.76 Mn
Sep 30, 2020 800,000.00
Sep 30, 2020 800,000.00